Skip to main content

Cognition Therapeutics, Inc. (CGTX) Stock Forecast

Data as of May 8, 2026

Healthcare · Current price $1.19 (+2.16%)

Consensus Target
Upside
Analysts
4
Rating
Buy(2.00)

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

CGTX vs Sector & Market

MetricCGTXHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count4818
Target Upside+1148.8%+14.9%
P/E Ratio-4.853.1127.95

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$19M$19M$19M2
2027-12-31$42M$42M$42M2
2028-12-31$4M$4M$4M1
2029-12-31$45M$45M$45M1
2030-12-31$113M$113M$113M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.45$-0.32$-0.144
2027-12-31$-0.50$-0.30$-0.193
2028-12-31$-0.29$-0.29$-0.291
2029-12-31$-0.25$-0.25$-0.251
2030-12-31$-0.19$-0.19$-0.191

Frequently Asked Questions

What is the analyst consensus for CGTX?

The consensus among 4 analysts covering Cognition Therapeutics, Inc. (CGTX) is Buy with an average price target of N/A.

How many analysts cover CGTX?

4 analysts have issued ratings for Cognition Therapeutics, Inc. in the past 12 months.

Is CGTX a buy or sell right now?

Based on 4 analyst ratings, CGTX has a consensus rating of Buy (2.00/5) with a N/A upside to the consensus target of N/A.

What are the earnings estimates for CGTX?

Analysts estimate CGTX will report EPS of $-0.32 for the period ending 2026-12-31, with revenue estimated at $19M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.